

Approved



**Democratic Republic of the Congo**  
**Country Operational Plan**  
**FY 2018**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		814,591		814,591	185,211	999,802
USAID		23,927,972	9,200,000	33,127,972	5,347,682	38,475,654
DOD		2,920,342		2,920,342	625,688	3,546,030
HHS/CDC	825,000	15,282,647		16,107,647	6,053,787	22,161,434
State/AF		312,080		312,080	0	312,080
<b>Total</b>	<b>825,000</b>	<b>43,257,632</b>	<b>9,200,000</b>	<b>53,282,632</b>	<b>12,212,368</b>	<b>65,495,000</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency					Total
	State	DOD	HHS/CDC	State/AF	USAID	
CIRC	0	0	0	0	0	0
HBHC	11,400	481,906	1,942,885	0	3,325,098	5,761,289
HKID	0	223,673	1,775,606	0	2,721,614	4,720,893
HLAB	0	58,486	268,918	0	195,317	522,721
HMBL	0	0	3,891	0	0	3,891
HMIN	0	10,208	0	0	6,084	16,292
HTXD	29,372	4,990	36,775	0	11,600,889	11,672,026
HTXS	128,887	835,748	3,137,401	0	5,513,823	9,615,859
HVAB	0	0	0	116,040	24,639	140,679
HVCT	29,372	81,912	440,700	0	1,995,042	2,547,026
HVMS	442,816	233,750	3,134,979		797,274	4,608,819
HVOP	14,250	307,941	106,983	116,040	1,345,024	1,890,238
HVSI	118,594	67,073	809,529	0	181,614	1,176,810

Approved



HVTB	0	64,864	800,442	0	688,742	<b>1,554,048</b>
IDUP	0	0	0	0	0	<b>0</b>
MTCT	28,500	199,757	1,408,625	0	1,507,388	<b>3,144,270</b>
OHSS	11,400	248,579	240,436	80,000	2,042,076	<b>2,622,491</b>
PDCS	0	66,528	797,294	0	699,393	<b>1,563,215</b>
PDTX	0	34,927	1,203,183	0	483,955	<b>1,722,065</b>
	<b>814,591</b>	<b>2,920,342</b>	<b>16,107,647</b>	<b>312,080</b>	<b>33,127,972</b>	<b>53,282,632</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	5,470,334
HKID	4,503,140
HVTB	1,471,464
PDCS	1,463,863
<b>Total Technical Area Planned Funding:</b>	<b>12,908,801</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	328,269
HVSI	731,631
OHSS	2,306,152
<b>Total Technical Area Planned Funding:</b>	<b>3,366,052</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	0
HMBL	0
HMIN	6,049
HVAB	140,679
HVCT	2,420,388
HVOP	1,774,409
IDUP	0
MTCT	3,014,735
<b>Total Technical Area Planned Funding:</b>	<b>7,356,260</b>



Approved



**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>
HTXD	11,556,778
HTXS	9,184,491
PDTX	1,612,901
<b>Total Technical Area Planned Funding:</b>	<b>22,354,170</b>

## Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	98 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	240,953
	Number of new ANC and L&D clients	245,874
	By Age (Denominator): Unknown Age	0
	By Age (Denominator): <10	0
	By Age (Denominator): 10-14	471
	By Age (Denominator): <15-19	32,791
	By Age (Denominator): 20-24	64,515
	By Age (Denominator): 50+	1,085
	By Number of known positives: Unknown Age	0
	By Number of known positives: <10	0
	By Number of known positives: 10-14	0
	By Number of known positives: 15-19	25
	By Number of known positives: 20-24	120
	By Number of known positives: 50+	0
By Number of new positives:	0	



	Unknown Age	
	By Number of new positives: <10	0
	By Number of new positives: 10-14	0
	By Number of new positives: 15-19	138
	By Number of new positives: 20-24	570
	By Number of new positives: 50+	2
	By Number of new negative: Unknown Age	0
	By Number of new negative: <10	0
	By Number of new negative: 10-14	424
	By Number of new negative: 15-19	32,562
	By Number of new negative: 20-24	63,641
	By Number of new negative: 50+	353
	By Age (Numerator): Unknown Age	0
	By Age (Numerator): <10	0
	By Age (Numerator): 10-14	427
	By Age (Numerator): 15-19	32,975
	By Age (Numerator): 20-24	64,596
	By Age (Numerator): 50+	355
	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	36,753
	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	36,753
	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	36,753
	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	36,753
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	263
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	131,425



PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	1,656
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	263
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	2,436
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	43
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	263
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,436
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	43
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	263
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2,436
PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	43
PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	133,591
PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	2,954
PMTCT_STAT_N_DSD_Age_Sex	2,954



	35-39, Female	
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	2,954
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,641
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	240,953
	New on ART	2,447
	Already on ART at beginning of current pregnancy	1,194
	PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)
Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.		63,702
Age/sex: 10-14 Male		160
Age/sex: 15-19 Male		8,986
Age/sex: 20-24 Male		14,083
Age/sex: 50+ Male		1,849



	Age/sex: 10-14 Female	158
	Age/sex: 15-19 Female	1,958
	Age/sex: 20-24 Female	9,364
	Age/sex: 50+ Female	1,263
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	3,228
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	3,236
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	3,228
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	3,236
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	3,228
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	3,236
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	3,227
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	3,237
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	34,120
	By key population type: Men who have sex with men who are NOT	4,775



	sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	29,345
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	23,296
	Total number of registered new and relapsed TB cases, during the reporting period.	23,298
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,081
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12,680



	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,090
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8,401
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,071
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	12,623
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,070
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8,546
HTS_SELF_DSD	HTS_SELF_N_DSD	502
	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	302
	HTS_SELF_N_DSD_HIVSelfTest Unassisted	502
	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	502
	HTS_SELF_N_DSD_KeyPop_HIV	302





	SelfTest FSW, Unassisted	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,268,135
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	5,023
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	61
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	4,075
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	36
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	6,107
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	54
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	3,589
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	18
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	7,678
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	174
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	4,346
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	27
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	4,715
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	294
Service Delivery Point (Facility)	4,843	



	Inpatient: 50+, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	226
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Inpatient: <1, Negative	1,611
	Service Delivery Point (Facility) Inpatient: <1, Positive	23
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	26,478
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	303
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	369
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	32
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	332
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	20



	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	4,855
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	82
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	2,141
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	28
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	8,158
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	209
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	4,371
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	50
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	544
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	13
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	508
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	5



	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Negative	0
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	0
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	0
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	0
	Service Delivery Point (Community) Mobile Testing: <1, Negative	372
	Service Delivery Point (Community) Mobile Testing: <1, Positive	0
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	854
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	0
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	32,577
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	382
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	27,874
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	392
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	41,591
	Service Delivery Point (Facility) Other PITC: 15-19, Female,	387



	Positive	
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	19,346
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	112
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	64,642
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,135
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	27,879
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	291
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	29,578
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,355
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	28,217
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1,056
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male,	0



	Positive	
	Service Delivery Point (Facility) Other PITC: <1, Negative	5,718
	Service Delivery Point (Facility) Other PITC: <1, Positive	125
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	150,308
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	2,059
	Service Delivery Point (Facility) Pediatric : <5 Negative	23,541
	Service Delivery Point (Facility) Pediatric : <5 Positive	282
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	369
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	12
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	315
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	11
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	916
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	20
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	894
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	11
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	1,270
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	58
	Service Delivery Point (Facility) TB:	1,604



	20-24, Male, Negative	
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	29
	Service Delivery Point (Facility) TB: 50+, Female, Negative	1,339
	Service Delivery Point (Facility) TB: 50+, Female, Positive	115
	Service Delivery Point (Facility) TB: 50+, Male, Negative	2,086
	Service Delivery Point (Facility) TB: 50+, Male, Positive	114
	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) TB: <1, Negative	102
	Service Delivery Point (Facility) TB: <1, Positive	2
	Service Delivery Point (Facility) TB: 1-9, Negative	1,012
	Service Delivery Point (Facility) TB: 1-9, Positive	38
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,633
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	65
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,520
	Service Delivery Point (Facility)	65



	Index: 10-14, Male, Positive	
	Service Delivery Point (Facility)	3,317
	Index: 15-19, Female, Negative	
	Service Delivery Point (Facility)	127
	Index: 15-19, Female, Positive	
	Service Delivery Point (Facility)	2,670
	Index: 15-19, Male, Negative	
	Service Delivery Point (Facility)	179
	Index: 15-19, Male, Positive	
	Service Delivery Point (Facility)	2,465
	Index: 20-24, Female, Negative	
	Service Delivery Point (Facility)	246
	Index: 20-24, Female, Positive	
	Service Delivery Point (Facility)	2,288
	Index: 20-24, Male, Negative	
	Service Delivery Point (Facility)	61
	Index: 20-24, Male, Positive	
	Service Delivery Point (Facility)	914
	Index: 50+, Female, Negative	
	Service Delivery Point (Facility)	242
	Index: 50+, Female, Positive	
	Service Delivery Point (Facility)	2,014
	Index: 50+, Male, Negative	
	Service Delivery Point (Facility)	333
	Index: 50+, Male, Positive	
	Service Delivery Point (Facility)	0
	Index: Unknown Age, Female, Negative	
	Service Delivery Point (Facility)	0
	Index: Unknown Age, Female, Positive	
	Service Delivery Point (Facility)	0
	Index: Unknown Age, Male, Negative	





Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
Service Delivery Point (Facility) Index: <1, Negative	287
Service Delivery Point (Facility) Index: <1, Positive	40
Service Delivery Point (Facility) Index: 1-9, Negative	6,727
Service Delivery Point (Facility) Index: 1-9, Positive	523
By Key Population: FSW, Negative	28,304
By Key Population: FSW, Positive	1,158
By Key Population: MSM, Negative	6,327
By Key Population: MSM, Positive	134
By Key Population: TG, Negative	69
By Key Population: TG, Positive	7
Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	107
Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	7
Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	73
Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	234
Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	12
Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	57
Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	1
Service Delivery Point (Community)	370



	Index Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	63
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	101
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	21
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	10
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	4
	Service Delivery Point (Community) Index Mod: 1-9, Negative	7
	Service Delivery Point (Community) Index Mod: 1-9, Positive	7
	Service Delivery Point (Facility) ANC: <1, Negative	0
	Service Delivery Point (Facility) ANC: <1, Positive	0
	Service Delivery Point (Facility) ANC: 10-14, Negative	402
	Service Delivery Point (Facility) ANC: 10-14, Positive	4
	Service Delivery Point (Facility) ANC: 15-19, Negative	34,129
	Service Delivery Point (Facility) ANC: 15-19, Positive	144
	Service Delivery Point (Facility) ANC: 1-9, Negative	0
	Service Delivery Point (Facility) ANC: 1-9, Positive	0
	Service Delivery Point (Facility) ANC: 20-24, Negative	64,114



	Service Delivery Point (Facility) ANC: 20-24, Positive	524
	Service Delivery Point (Facility) ANC: 50+, Negative	383
	Service Delivery Point (Facility) ANC: 50+, Positive	6
	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	1,094
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	56
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	962
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	45
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	2,857
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	60
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2,593
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	27
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	5,232
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	257
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	5,714
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	98



	Service Delivery Point (Facility) VCT: 50+, Female, Negative	1,643
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	186
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	2,445
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	193
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) VCT:	0
	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) VCT: <1, Negative	177
	Service Delivery Point (Facility) VCT: <1, Positive	26
	Service Delivery Point (Facility) VCT: 1-9, Negative	3,151
	Service Delivery Point (Facility) VCT: 1-9, Positive	287
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	616
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	7
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	384
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	8



Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	707
Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	23
Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	746
Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	21
Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	77
Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	7
Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	18
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	2,974
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	550
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	3,004
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	554
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	2,974
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	549
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	3,004
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	551
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	2,974
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	548



HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	3,004
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	550
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	2,974
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	550
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	3,004
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	546
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	3,986
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	295
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	3,987
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	311
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	3,986
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	295
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	3,987
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	311
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	3,981
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	294
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	3,982



HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Positive	310
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Negative	3,971
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Positive	293
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	3,972
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	310
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Negative	2,935
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Positive	82
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Negative	3,227
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Positive	95
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Negative	3,059
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Positive	81
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Negative	3,019
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Positive	76
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Negative	3,246
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Positive	78



	Sex_Result 35-39, Female, Positive	
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	3,245
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	79
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	2,781
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	74
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	2,781
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	73
	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	1,878
	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	110
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	113
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	19
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	113
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	19
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	113
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	19





	Sex_Result 30-34, Female, Positive	
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	113
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	19
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	113
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	19
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	113
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	19
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	113
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	19
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	113
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	19
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	33,583
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	1,426
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	33,082



HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	1,418
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	33,583
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	1,426
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	33,082
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	1,413
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	33,483
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	1,420
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	33,082
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	1,415
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	33,483
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	1,401
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	33,082
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	1,400
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	34,174



HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	424
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	34,174
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	424
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	34,174
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	424
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	34,174
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	424
HTS_TST_N_DSD_STI_Age_Sex_Result <1, Unknown Sex, Negative	0
HTS_TST_N_DSD_STI_Age_Sex_Result <1, Unknown Sex, Positive	0
HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Negative	50
HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Positive	4
HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Negative	54
HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Positive	2
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	30



HTS_TST_N_DSD_STI_Age_Sex_ Result 15-19, Female, Positive	1
HTS_TST_N_DSD_STI_Age_Sex_ Result 15-19, Male, Negative	20
HTS_TST_N_DSD_STI_Age_Sex_ Result 15-19, Male, Positive	1
HTS_TST_N_DSD_STI_Age_Sex_ Result 1-9, Unknown Sex, Negative	0
HTS_TST_N_DSD_STI_Age_Sex_ Result 1-9, Unknown Sex, Positive	0
HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Female, Negative	30
HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Female, Positive	2
HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Male, Negative	20
HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Male, Positive	1
HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Female, Negative	40
HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Female, Positive	4
HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Negative	50
HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Positive	3
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Negative	30
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Positive	3
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Negative	40
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Positive	2



HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Negative	40
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Positive	2
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Negative	50
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Positive	1
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Negative	30
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Positive	1
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Negative	30
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Positive	1
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Negative	4
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Positive	0
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Negative	4
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Positive	0
HTS_TST_N_DSD_STI_Age_Sex_ Result Unknown Age, Female, Negative	0
HTS_TST_N_DSD_STI_Age_Sex_ Result Unknown Age, Female, Positive	0
HTS_TST_N_DSD_STI_Age_Sex_ Result Unknown Age, Male, Negative	0
HTS_TST_N_DSD_STI_Age_Sex_ Result Unknown Age, Male, Positive	0



	Result Unknown Age, Male, Positive	
	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	1,360
	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	124
	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	1,369
	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	122
	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	1,363
	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	124
	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	1,372
	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	121
	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	1,376
	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	123
	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	1,385
	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	121
	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	1,370
	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	123
	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	1,379
	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	121



HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	3,358
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	250
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	3,434
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	255
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	3,358
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Positive	250
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	3,434
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	255
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Negative	3,358
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	250
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	3,434
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Positive	255
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Negative	3,358
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	250
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative	3,334
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	255
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female,	211



	Negative	
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Positive	16
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Negative	211
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Positive	16
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Female, Negative	211
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Female, Positive	16
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Male, Negative	211
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Male, Positive	16
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 35-39, Female, Negative	211
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 35-39, Female, Positive	16
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 35-39, Male, Negative	211
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 35-39, Male, Positive	16
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 40-49, Female, Negative	211
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 40-49, Female, Positive	16





	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	211
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	16
GEND_GBVDSD	Number of people receiving post-GBV care	402
	By type of service: Sexual Violence (Post-Rape Care)	406
	By PEP service provision (related to sexual violence services provided)	25
	<10, Female, Sexual Violence (Post-Rape Care)	33
	10-14, Female, Sexual Violence (Post-Rape Care)	35
	10-14, Male, Sexual Violence (Post-Rape Care)	2
	15-19, Female, Sexual Violence (Post-Rape Care)	48
	20-24, Female, Sexual Violence (Post-Rape Care)	30
	50+, Female, Sexual Violence (Post-Rape Care)	1
	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	256
	OVC_SERVDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS
Age/Sex: 10-14 Male		5,876
Age/Sex: 15-17 Male		4,025
By: Age/sex: Male 18-24		675
By: Age/sex: Male 25+		1,438



	Age/Sex: 10-14 Female	6,006
	Age/Sex: 15-17 Female	4,263
	By: Age/sex: 18-24 Female	799
	By: Age/sex: 25+ Female	3,026
	Sum of Age/Sex disaggregates	20,170
	Age/Sex: <1	2,570
	Age/Sex: 1-9	13,674
	Program Completion: Active	39,411
	Program Completion: Graduation	2,918
	Program Completion: Transferred	0
	Program Completion: Exited without graduation	0
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	86 %
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	36,407
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	42,329
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,401



	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	68
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,010
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	74
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,265
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	82 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	20,690
	The number of ART patients who	25,104



	were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
	By Age/Sex (Denominator): <15, Female	1,026
	By Age/Sex (Denominator): <15, Male	1,082
	By Age/Sex (Denominator): 15+, Female	15,806
	By Age/Sex (Denominator): 15+, Male	7,208
	By Age/Sex (Numerator): <15, Female	924
	By Age/Sex (Numerator): <15, Male	931
	By Age/Sex (Numerator): 15+, Female	13,257
	By Age/Sex (Numerator): 15+, Male	5,576
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	15,055
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	10,037
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	12,417
	TB_PREV_N_DSD_TherapyType_	8,259



	NewExArt_HIV IPT, Life-long ART, New, Positive	
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	119,293
	Denominator: By Aggregated Age/Sex: <15, Female	4,701
	Denominator: By Aggregated Age/Sex: <15, Male	3,738
	Denominator: By Aggregated Age/Sex:15+, Female	77,937
	Denominator: By Aggregated Age/Sex:15+, Male	32,459
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	4,068
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	3,222
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	943
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	58,461
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,190
	TX_TB_D_DSD_TBScreen_NewEx	58,461



	istingART_HIV Life-long ART, New, TB Screen - Negative, Positive	
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	1,190
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,523
	By infants who received a virologic test within 2 months of birth	2,842
	By infants who received their first virologic HIV test between 2 and 12 months of age	681
	Sum of Infant Age disaggregates	3,523
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	119,786
	Age/Sex: 15-19 Male	896
	Age/Sex: 15-19 Female	2,117
	Age/Sex: <1	513
	Age/Sex: <1-9	9,338
	Age/Sex: 10-14 Male	1,980
	Age/Sex: 10-14 Female	2,079
	Age/Sex: 20-24 Male	2,008
	Age/Sex: 50+ Male	8,164
	Age/Sex: 20-24 Female	7,657
	Age/Sex: 50+ Female	12,627
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	8,993
	TX_CURR_N_DSD_Age_Sex_HIV	8,975



	Status 25-29, Male, Positive	
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	8,993
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	8,975
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	8,993
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	8,975
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	8,993
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	8,975
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	38,162
	By Age/Sex: <1	410
	By Age/Sex: 1-9	575
	By Age/Sex: 10-14 Male	461
	By Age/Sex: 15-19 Male	190
	By Age/Sex: 20-24 Male	458
	By Age/Sex: 50+ Male	2,080
	By Age/Sex: 10-14 Female	3,219
	By Age/Sex: 15-19 Female	854
	By Age/Sex: 20-24 Female	2,643
	By Age/Sex: 50+ Female	2,839
	Pregnancy status	3,267
	Breastfeeding status	1,111
	FSW	1,227
	MSM	177
	TG	13
TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	3,035	



	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	3,042
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	3,035
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	3,042
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	3,035
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	3,042
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	3,035
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	3,042
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	97,725
	<15, Undocumented Test Indication, Male	4
	15+, Undocumented Test Indication, Male	1
	Denominator: Indication: Routine	95,695
	Denominator: Indication: Targeted	2,040
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	509





	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	512
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	510
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	519
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	23,920
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	23,902
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	23,942
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	23,947
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	90 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	28,815
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	31,917
	Numerator by Status: Breastfeeding	548
	Denominator by Status: Pregnant	2,775
	Denominator by Status: Breastfeeding	521
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and	1,591



	children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,445
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,969
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,692
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,765
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,288
	Aggregated Age/Sex: <15 Female (Denominator: Total number of	2,156



	<p>adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>19,449</p>



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
11054	Population Services International	NGO	U.S. Department of Defense		
13017	American Society for Microbiology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
13094	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
13623	FHI 360	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
14831	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	312,080
16963	Elizabeth Glaser	NGO	U.S. Department		



	Pediatric AIDS Foundation		of Health and Human Services/Centers for Disease Control and Prevention		
17177	SANRU	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	611,280
17628	Catholic Relief Services	FBO	U.S. Agency for International Development		
17630	Education Development Center	NGO	U.S. Agency for International Development	GHP-State	2,621,224
18090	FHI 360	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	2,000,004
18092	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-USAID	6,162,422
18093	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Agency for International Development	GHP-State	2,717,423
18096	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	10,154,812



18097	FHI 360	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	368,282
18316	UNAIDS - Joint United Nations Programme on HIV/AIDS	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
18370	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	13,806,519
70063	TBD	TBD	Redacted	Redacted	Redacted
70064	TBD	TBD	Redacted	Redacted	Redacted
70065	TBD	TBD	Redacted	Redacted	Redacted
70066	TBD	TBD	Redacted	Redacted	Redacted
70067	TBD	TBD	Redacted	Redacted	Redacted
70068	TBD	TBD	Redacted	Redacted	Redacted
70069	Remote Medical International	Private Contractor	U.S. Agency for International Development	GHP-State	1,290,294
70070	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	2,789,929



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 11054</b>	<b>Mechanism Name: HIV/AIDS activities in the DRC Armed Forces</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	11054	
<b>Mechanism Name:</b>	HIV/AIDS activities in the DRC Armed Forces	
<b>Prime Partner Name:</b>	Population Services International	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0





Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13017</b>	<b>Mechanism Name: Global Laboratory Capacity Strengthening Program</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13017 <b>Mechanism Name:</b> Global Laboratory Capacity Strengthening Program <b>Prime Partner Name:</b> American Society for Microbiology		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

**Implementing Mechanism Indicator Information**



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13094</b>	<b>Mechanism Name: Association of Public Health Laboratories Centrally funded CoAG</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13094	
<b>Mechanism Name:</b>	Association of Public Health Laboratories Centrally funded	
<b>Prime Partner Name:</b>	CoAG Association of Public Health Laboratories	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13623</b>	<b>Mechanism Name: Providing Capacity-Building Assistance to Government and Indigenous Congolese Organizations to Improve HIV/AIDS Service Delivery in the Democratic Republic of Congo under PEPFAR</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
<b>Total All Funding Sources: 0</b>		<b>Total Mechanism Pipeline: N/A</b>



<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13623	
<b>Mechanism Name:</b>	Providing Capacity-Building Assistance to Government and Indigenous Congolese Organizations to Improve HIV/AIDS	
<b>Prime Partner Name:</b>	Service Delivery in the Democratic Republic of Congo under PEPFAR	
	FHI 360	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0





Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 14831</b>	<b>Mechanism Name: Small Grant Programs</b>
Funding Agency: State/AF	Procurement Type: Inter-Agency Agreement
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 312,080</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 312,080</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	312,080

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	<b>14831</b>
<b>Mechanism Name:</b>	<b>Small Grant Programs</b>
<b>Prime Partner Name:</b>	<b>U.S. Department of State</b>



Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	80,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	116,040
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	116,040
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16963</b>	<b>Mechanism Name: Increase Access to Comprehensive HIV/AIDS Prevention Care and Treatment Services in the Democratic Republic of Congo under (PEPFAR) (KIMIA)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	16963	
<b>Mechanism Name:</b>	Increase Access to Comprehensive HIV/AIDS Prevention Care and Treatment Services in the Democratic Republic of Congo	
<b>Prime Partner Name:</b>	under (PEPFAR) (KIMIA) Elizabeth Glaser Pediatric AIDS Foundation	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	369
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,271
PMTCT_ART_DSD	New on ART	184
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	185
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,271
PMTCT_STAT_DSD	Number of new ANC and L&D clients	27,832
PMTCT_STAT_DSD	By Age (Denominator): 10-14	90
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,528
PMTCT_STAT_DSD	By Age (Denominator): 20-24	5,573
PMTCT_STAT_DSD	By Age (Denominator): 50+	153
PMTCT_STAT_DSD	By Number of new positives: 15-19	14
PMTCT_STAT_DSD	By Number of new positives: 20-24	36
PMTCT_STAT_DSD	By Number of new negative: 10-14	52
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,911
PMTCT_STAT_DSD	By Number of new negative: 20-24	6,405
PMTCT_STAT_DSD	By Number of new negative: 50+	84
PMTCT_STAT_DSD	By Age (Numerator): 10-14	52
PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,925



PMTCT_STAT_DSD	By Age (Numerator): 20-24	6,442
PMTCT_STAT_DSD	By Age (Numerator): 50+	84
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	4,872
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	4,872
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	4,872
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	4,872
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	48
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	17,450
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	142
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	48
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	48
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	48
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	17,628
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	39
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	39
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	39
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,450
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	200
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive	2,250



	interventions that are based on evidence and/or meet the minimum standards required)	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	156,479
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	905
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	586
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	604
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	386
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	673
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	389
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	293
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	313
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	3





	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	2,428
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	5,011
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	90
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	4,454
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	94
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	4,802
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	2,856
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	8,114
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	116
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,573
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	5,924
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	283
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	5,880
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	204



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	22,891
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	261
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	147
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	49
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	155
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	175
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	207
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	302
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female,	213



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	348
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	254
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	190
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	623
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	598
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	401
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	266
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	181
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	118
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	227
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	42



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	771
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	61
HTC_TST_DSD	By Key Population: FSW, Negative	1,966
HTC_TST_DSD	By Key Population: FSW, Positive	52
HTC_TST_DSD	By Key Population: MSM, Negative	327
HTC_TST_DSD	By Key Population: MSM, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	2,910
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	6,417
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	66
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	88
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	400
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	419
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	717
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male,	609



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	204
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	242
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	219
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	219
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	219
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	219
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	219
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	219
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	53



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	219
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	219
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	269
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	267
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	269
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	267
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	269
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	267
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	8



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	269
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	267
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	4,836
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	189
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	4,835
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	188
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	4,836
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	189
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	4,835
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	188
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	4,836
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	189
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	4,835



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	188
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	4,836
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	189
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	4,835
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	188
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	4,362
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	4,362
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	4,362
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	4,362
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	16





	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	284
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	283
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	284



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	283
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	284
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	283
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	284
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	283
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	8
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,388
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,387
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	137
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,962
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	140



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,137
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	84
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,811
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	117
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,178
GEND_GBV_DSD	Number of people receiving post-GBV care	25
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	25
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	25
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	8
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	5,804
OVC_SERV_DSD	Age/Sex: 10-14 Male	787
OVC_SERV_DSD	Age/Sex: 15-17 Male	529
OVC_SERV_DSD	By: Age/sex: Male 18-24	113
OVC_SERV_DSD	By: Age/sex: Male 25+	167
OVC_SERV_DSD	Age/Sex: 10-14 Female	827
OVC_SERV_DSD	Age/Sex: 15-17 Female	624



OVC_SERV_DSD	By: Age/sex: 18-24 Female	141
OVC_SERV_DSD	By: Age/sex: 25+ Female	393
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,767
OVC_SERV_DSD	Age/Sex: <1	412
OVC_SERV_DSD	Age/Sex: 1-9	1,825
OVC_SERV_DSD	Program Completion: Active	5,397
OVC_SERV_DSD	Program Completion: Graduation	407
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	4,992
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	5,804
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	248
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	72
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	163
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	350



PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	289
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	61
PMTCT_EID_DSD	Sum of Infant Age disaggregates	350
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	16,447
TX_CURR_DSD	Age/Sex: 15-19 Male	172
TX_CURR_DSD	Age/Sex: 15-19 Female	252
TX_CURR_DSD	Sum of age/sex disaggregates	424
TX_CURR_DSD	Age/Sex: <1	39
TX_CURR_DSD	Age/Sex: <1-9	1,214
TX_CURR_DSD	Age/Sex: 10-14 Male	461
TX_CURR_DSD	Age/Sex: 10-14 Female	364
TX_CURR_DSD	Age/Sex: 20-24 Male	122
TX_CURR_DSD	Age/Sex: 50+ Male	1,505
TX_CURR_DSD	Age/Sex: 20-24 Female	537
TX_CURR_DSD	Age/Sex: 50+ Female	2,105
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,205
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,207
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,205
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,207
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,205
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,207
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,205
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male,	1,207



	Positive	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,012
TX_NEW_DSD	By Age/Sex: <1	65
TX_NEW_DSD	By Age/Sex: 1-9	84
TX_NEW_DSD	By Age/Sex: 10-14 Male	86
TX_NEW_DSD	By Age/Sex: 15-19 Male	34
TX_NEW_DSD	By Age/Sex: 20-24 Male	26
TX_NEW_DSD	By Age/Sex: 50+ Male	284
TX_NEW_DSD	By Age/Sex: 10-14 Female	287
TX_NEW_DSD	By Age/Sex: 15-19 Female	85
TX_NEW_DSD	By Age/Sex: 20-24 Female	226
TX_NEW_DSD	By Age/Sex: 50+ Female	428
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,456
TX_NEW_DSD	Pregnancy status	270
TX_NEW_DSD	Breastfeeding status	53
TX_NEW_DSD	FSW	50
TX_NEW_DSD	MSM	12
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	300
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	305
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	300
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	305
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	300
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	305
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	300
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	305



	Positive	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	14,578
TX_PVLS_DSD	Denominator: Indication: Routine	14,567
TX_PVLS_DSD	Denominator: Indication: Targeted	11
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	2
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	2
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	3,645
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,640
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,649
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,639
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,967
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,408
TX_RET_DSD	Numerator by Status: Breastfeeding	55
TX_RET_DSD	Denominator by Status: Pregnant	245
TX_RET_DSD	Denominator by Status: Breastfeeding	71
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	265

TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	970
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	327
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,433
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	290
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,035
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	360
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,702
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,251
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly	2,649



	started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	78
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	77
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,864
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	629
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	85
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	72
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,574
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	516
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,586
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,056
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,353
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	899
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	16,445
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	595
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	631
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	11,214
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	4,020
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	481
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	375
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	108



TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	8,059
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	167
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	8,059
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	167

### Implementing Mechanism Details

<b>Mechanism ID: 17177</b>	<b>Mechanism Name: SANRU Clinical and PMTCT Scale-up</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: SANRU	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 611,280</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 1,188,720</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,800,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	611,280

### Cross-Cutting Budget Attribution(s)

Gender: GBV	125,000
Focus Area:	GBV Prevention
Sub Area:	Monitoring and Evaluation
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Monitoring and Evaluation



**Budget Code Information**

<b>Mechanism ID:</b> 17177		
<b>Mechanism Name:</b> SANRU Clinical and PMTCT Scale-up		
<b>Prime Partner Name:</b> SANRU		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	152,820
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	61,128
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	61,128
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	30,564
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	238,399
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	67,241

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission	181



	(MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	13,691
PMTCT_ART_DSD	New on ART	180
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	13,691
PMTCT_STAT_DSD	Number of new ANC and L&D clients	13,953
PMTCT_STAT_DSD	By Age (Denominator): 10-14	7
PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,701
PMTCT_STAT_DSD	By Age (Denominator): 20-24	4,041
PMTCT_STAT_DSD	By Number of new positives: 15-19	7
PMTCT_STAT_DSD	By Number of new positives: 20-24	29
PMTCT_STAT_DSD	By Number of new negative: 10-14	7
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,666
PMTCT_STAT_DSD	By Number of new negative: 20-24	3,925
PMTCT_STAT_DSD	By Number of new negative: 50+	2
PMTCT_STAT_DSD	By Age (Numerator): 10-14	7
PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,674
PMTCT_STAT_DSD	By Age (Numerator): 20-24	3,954
PMTCT_STAT_DSD	By Age (Numerator): 50+	2
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	2,051
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	2,051
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,051
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	2,051
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	7,906
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	149
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	8,051
KP_PREV_DSD	Number of key populations reached with individual	1,700



	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	400
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,300
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	56,636
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	124
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	87
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	293
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	152
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	241
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male,	175



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	83
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	70
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	101
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	990
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	646
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	534
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,418
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	748
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	3,568
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	92
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24,	1,175



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	859
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	94
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	796
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	590
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	4,262
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	198
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	77
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	62
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	116
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female,	5





	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	80
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	68
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	105
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	128
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	213
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	188
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	17



HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	357
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,648
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	3,868
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	129
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	87
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	86
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	11



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	252
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	252
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	252
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	252
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	252
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	252
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	252
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	252
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	110



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	835
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	8



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,901
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	129
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,902
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	132
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,901
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	129
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,902
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	132
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,901
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	129
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,902
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	132
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,901
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	129
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,902
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	132
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	1,997



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,997
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,997
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,997
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	10



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	112
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	109
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	112
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	109
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	112
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	109



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	112
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	109
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	12
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,334
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,334
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	87
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	645
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	89
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	514
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	87
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	646
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	87





TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	514
GEND_GBV_DSD	Number of people receiving post-GBV care	23
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	23
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	23
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,530
OVC_SERV_DSD	Age/Sex: 10-14 Male	220
OVC_SERV_DSD	Age/Sex: 15-17 Male	220
OVC_SERV_DSD	By: Age/sex: Male 18-24	54
OVC_SERV_DSD	By: Age/sex: Male 25+	54
OVC_SERV_DSD	Age/Sex: 10-14 Female	220
OVC_SERV_DSD	Age/Sex: 15-17 Female	220
OVC_SERV_DSD	By: Age/sex: 18-24 Female	54
OVC_SERV_DSD	By: Age/sex: 25+ Female	54
OVC_SERV_DSD	Sum of Age/Sex disaggregates	880
OVC_SERV_DSD	Age/Sex: <1	220
OVC_SERV_DSD	Age/Sex: 1-9	220
OVC_SERV_DSD	Program Completion: Active	1,423
OVC_SERV_DSD	Program Completion: Graduation	107
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	1,316
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,530
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	109
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The	2



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	34
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	72
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	178
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	148
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	30
PMTCT_EID_DSD	Sum of Infant Age disaggregates	178
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,461
TX_CURR_DSD	Age/Sex: 15-19 Male	25
TX_CURR_DSD	Age/Sex: 15-19 Female	128
TX_CURR_DSD	Sum of age/sex disaggregates	153
TX_CURR_DSD	Age/Sex: <1	44
TX_CURR_DSD	Age/Sex: <1-9	475
TX_CURR_DSD	Age/Sex: 10-14 Male	131
TX_CURR_DSD	Age/Sex: 10-14 Female	108
TX_CURR_DSD	Age/Sex: 20-24 Male	67
TX_CURR_DSD	Age/Sex: 50+ Male	293
TX_CURR_DSD	Age/Sex: 20-24 Female	429



TX_CURR_DSD	Age/Sex: 50+ Female	465
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	485
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	481
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	485
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	481
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	485
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	481
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	485
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	481
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,715
TX_NEW_DSD	By Age/Sex: <1	26
TX_NEW_DSD	By Age/Sex: 1-9	26
TX_NEW_DSD	By Age/Sex: 10-14 Male	29
TX_NEW_DSD	By Age/Sex: 15-19 Male	1
TX_NEW_DSD	By Age/Sex: 20-24 Male	32
TX_NEW_DSD	By Age/Sex: 50+ Male	104
TX_NEW_DSD	By Age/Sex: 10-14 Female	245
TX_NEW_DSD	By Age/Sex: 15-19 Female	69
TX_NEW_DSD	By Age/Sex: 20-24 Female	180
TX_NEW_DSD	By Age/Sex: 50+ Female	161
TX_NEW_DSD	Sum of Age/Sex disaggregates	821
TX_NEW_DSD	Pregnancy status	299
TX_NEW_DSD	Breastfeeding status	60
TX_NEW_DSD	FSW	6



TX_NEW_DSD	MSM	6
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	222
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	219
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	222
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	219
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	222
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	219
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	222
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	219
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,153
TX_PVLS_DSD	Denominator: Indication: Routine	4,984
TX_PVLS_DSD	Denominator: Indication: Targeted	171
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	42
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	44
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	42
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	44
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,248
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,245



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,249
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,247
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,550
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,724
TX_RET_DSD	Numerator by Status: Breastfeeding	62
TX_RET_DSD	Denominator by Status: Pregnant	83
TX_RET_DSD	Denominator by Status: Breastfeeding	58
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	82
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	327
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	98
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,026
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	90
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	398



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	115
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,119
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	940
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,106
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	51
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	81
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	699
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	275
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	41
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	70
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	594
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	235
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	664
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	442
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT,	564



	Life-long ART, Already, Positive	
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	376
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	5,995
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	231
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	179
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	3,875
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,705
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	11
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	8
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	3
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	2,939
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	60
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	2,939
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	60

### Implementing Mechanism Details

<b>Mechanism ID: 17628</b>	<b>Mechanism Name: Coordinating Comprehensive Care for Children (4Children)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17628</b>		
<b>Mechanism Name: Coordinating Comprehensive Care for Children (4Children)</b>		
<b>Prime Partner Name: Catholic Relief Services</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0





Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	0
-----------	------	---

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17630</b>	<b>Mechanism Name: Enhancing Services and Linkages for Children affected by HIV and AIDS (ELIKIA )</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Education Development Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,621,224</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 74,948</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,696,172</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,621,224

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	938,885
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID: 17630</b>
<b>Mechanism Name: Enhancing Services and Linkages for Children affected by HIV</b>



Prime Partner Name: and AIDS (ELIKIA ) Education Development Center		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	2,621,224
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	18,570
OVC_SERV_DSD	Age/Sex: 10-14 Male	2,574
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,579
OVC_SERV_DSD	By: Age/sex: Male 18-24	242
OVC_SERV_DSD	By: Age/sex: Male 25+	624
OVC_SERV_DSD	Age/Sex: 10-14 Female	2,627



OVC_SERV_DSD	Age/Sex: 15-17 Female	1,693
OVC_SERV_DSD	By: Age/sex: 18-24 Female	289
OVC_SERV_DSD	By: Age/sex: 25+ Female	1,446
OVC_SERV_DSD	Sum of Age/Sex disaggregates	8,473
OVC_SERV_DSD	Age/Sex: <1	779
OVC_SERV_DSD	Age/Sex: 1-9	6,719
OVC_SERV_DSD	Program Completion: Active	17,270
OVC_SERV_DSD	Program Completion: Graduation	1,300
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	15,969
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	18,570

### Implementing Mechanism Details

<b>Mechanism ID: 18090</b>	<b>Mechanism Name: Linkages Across the Continuum of HIV Services for Key Populations Affected by HIV (Linkages)</b>
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,000,004</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,000,004</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,178,219
GHP-USAID	821,785



**Cross-Cutting Budget Attribution(s)**

Key Populations: MSM and TG	469,597
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	1,095,726
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Human Resources for Health	434,677

**Budget Code Information**

<b>Mechanism ID:</b>	18090	
<b>Mechanism Name:</b>	Linkages Across the Continuum of HIV Services for Key Populations Affected by HIV (Linkages)	
<b>Prime Partner Name:</b>	FHI 360	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	260,693
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	245,140
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	24,639
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	26,161
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	1,207,045



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	236,326
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,350
PP_PREV_DSD	Age/sex: 10-14 Male	81
PP_PREV_DSD	Age/sex: 15-19 Male	410
PP_PREV_DSD	Age/sex: 20-24 Male	690
PP_PREV_DSD	Age/sex: 50+ Male	136
PP_PREV_DSD	Age/sex: 10-14 Female	89
PP_PREV_DSD	Age/sex: 15-19 Female	624
PP_PREV_DSD	Age/sex: 20-24 Female	752
PP_PREV_DSD	Age/sex: 50+ Female	94
PP_PREV_DSD	Sum of Age/Sex disaggregates	2,876
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	309





PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	309
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	309
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	309
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	309
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	309
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	309
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	310
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	17,295
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,300
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	13,995
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	40,022
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	4,110
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	63
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	1,342
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	6,931



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	183
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	3,076
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	260
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	214
HTC_TST_DSD	By Key Population: FSW, Negative	16,913
HTC_TST_DSD	By Key Population: FSW, Positive	705
HTC_TST_DSD	By Key Population: MSM, Negative	5,002
HTC_TST_DSD	By Key Population: MSM, Positive	93
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	234
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	57
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	370
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	101
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	4



HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	584
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	342
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	648
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	664
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	70
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	2,171
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	2,171
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	2,171
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	62



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	2,171
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	2,171
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	2,171
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	2,171
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	2,171
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	113

HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	16



HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	16
HTS_SELF_DSD	HTS_SELF_N_DSD	302
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	302
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	302
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	302
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	302

### Implementing Mechanism Details

<b>Mechanism ID: 18092</b>	<b>Mechanism Name: Integrated HIV/AIDS Project Haut-Katanga/Lualaba</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 6,162,422</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 2,110,689</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 8,273,111</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	6,162,422

**Cross-Cutting Budget Attribution(s)**

Water	100,000
Human Resources for Health	1,519,395

**Budget Code Information**

<b>Mechanism ID: 18092</b>		
<b>Mechanism Name: Integrated HIV/AIDS Project Haut-Katanga/Lualaba</b>		
<b>Prime Partner Name: Program for Appropriate Technology in Health</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	1,130,467
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	464,562
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	203,832
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	147,567



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	299,606
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	232,280
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	53,480
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	1,016,137
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount





Treatment	HTXS	2,289,297
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	325,194

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,498
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	78,544
PMTCT_ART_DSD	New on ART	997
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	501
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	78,544
PMTCT_STAT_DSD	Number of new ANC and L&D clients	80,154
PMTCT_STAT_DSD	By Age (Denominator): 10-14	157
PMTCT_STAT_DSD	By Age (Denominator): <15-19	11,273
PMTCT_STAT_DSD	By Age (Denominator): 20-24	21,494
PMTCT_STAT_DSD	By Age (Denominator): 50+	710
PMTCT_STAT_DSD	By Number of known positives: 15-19	7
PMTCT_STAT_DSD	By Number of known positives: 20-24	48
PMTCT_STAT_DSD	By Number of new positives: 15-19	61
PMTCT_STAT_DSD	By Number of new positives: 20-24	269
PMTCT_STAT_DSD	By Number of new negative: 10-14	152
PMTCT_STAT_DSD	By Number of new negative: 15-19	11,303
PMTCT_STAT_DSD	By Number of new negative: 20-24	21,205
PMTCT_STAT_DSD	By Number of new negative: 50+	70



PMTCT_STAT_DSD	By Age (Numerator): 10-14	155
PMTCT_STAT_DSD	By Age (Numerator): 15-19	11,364
PMTCT_STAT_DSD	By Age (Numerator): 20-24	21,523
PMTCT_STAT_DSD	By Age (Numerator): 50+	70
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	11,630
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	11,630
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	11,630
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	11,630
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	113
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	44,281
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	701
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	113
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	113
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	113
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	45,093
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	103
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	103
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	103
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,798
PP_PREV_DSD	Age/sex: 10-14 Male	63
PP_PREV_DSD	Age/sex: 15-19 Male	76
PP_PREV_DSD	Age/sex: 20-24 Male	149
PP_PREV_DSD	Age/sex: 50+ Male	64
PP_PREV_DSD	Age/sex: 10-14 Female	58
PP_PREV_DSD	Age/sex: 15-19 Female	194



PP_PREV_DSD	Age/sex: 20-24 Female	273
PP_PREV_DSD	Age/sex: 50+ Female	45
PP_PREV_DSD	Sum of Age/Sex disaggregates	922
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	102
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	110
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	102
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	110
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	102
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	110
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	102
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	110
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	15
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	15
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	287,358
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,125
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	924
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,654
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	28



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	871
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,207
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,190
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	978
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	954
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	97
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	704
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	6,158
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	126
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	45
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	71
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	2



	20-24, Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	57
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	5,091
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	98
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	3,951
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	113
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	7,705
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	112
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	2,718
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	12,992
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	353
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,657
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	88
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	3,106
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	283
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male,	3,301



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	206
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	2,499
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	23,470
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	712
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	10,870
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	189
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	67
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	61
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	204
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	181
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	265
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male,	348



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	333
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	543
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	224
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	330
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	283
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	417
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	254
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	277
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	45

HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	825
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	741
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	91
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	183
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,802
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	209
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	107
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	73
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	7





HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	125
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	11,830
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	21,494
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	230
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	76
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	379
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	384
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	859
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	789
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,455
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	138
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,467
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	442



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	501
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	103
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	1,060
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	174
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,418
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	240
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,423
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	238
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	1,418
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	240
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,423
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	238
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	1,418
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	240
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,423
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	238



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	1,418
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	240
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	1,423
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	238
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1,273
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	110
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1,277
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	112
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	1,273
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	110
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,277
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	112
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	1,273
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	110
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,277
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	112
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	1,273



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	110
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	1,277
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	112
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	631
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	1



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	6,387
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	419
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	6,386
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	425
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	6,387
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	419
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	6,386
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	425
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	6,387
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	419
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	6,386
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	425
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	6,387



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	419
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	6,386
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	425
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	10,878
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	186
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	10,878
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	186
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	10,878
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	186
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	10,878
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	186
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	360
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	359
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	360
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	40



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	359
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	360
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	359
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	360
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	359
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1,095
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	162
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,090
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	168
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1,095
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	162
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,090



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	168
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	1,095
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	162
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,090
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	168
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	1,095
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	162
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,090
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	168
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,796
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	5,797
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	210
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,223
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	244
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,111





TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	215
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,220
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	240
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,118
GEND_GBV_DSD	Number of people receiving post-GBV care	95
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	95
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	95
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	659
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	15
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	312
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	18
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	314



PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,452
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,154
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	298
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,452
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	42,682
TX_CURR_DSD	Age/Sex: 15-19 Male	337
TX_CURR_DSD	Age/Sex: 15-19 Female	847
TX_CURR_DSD	Sum of age/sex disaggregates	1,184
TX_CURR_DSD	Age/Sex: <1	231
TX_CURR_DSD	Age/Sex: <1-9	3,654
TX_CURR_DSD	Age/Sex: 10-14 Male	652
TX_CURR_DSD	Age/Sex: 10-14 Female	745
TX_CURR_DSD	Age/Sex: 20-24 Male	1,202
TX_CURR_DSD	Age/Sex: 50+ Male	2,559
TX_CURR_DSD	Age/Sex: 20-24 Female	3,450
TX_CURR_DSD	Age/Sex: 50+ Female	3,933
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,133
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3,129
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3,133
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	3,129
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	3,133
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,129
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49,	3,133



	Female, Positive	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	3,129
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	13,958
TX_NEW_DSD	By Age/Sex: <1	157
TX_NEW_DSD	By Age/Sex: 1-9	185
TX_NEW_DSD	By Age/Sex: 10-14 Male	155
TX_NEW_DSD	By Age/Sex: 15-19 Male	65
TX_NEW_DSD	By Age/Sex: 20-24 Male	179
TX_NEW_DSD	By Age/Sex: 50+ Male	648
TX_NEW_DSD	By Age/Sex: 10-14 Female	1,336
TX_NEW_DSD	By Age/Sex: 15-19 Female	337
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,067
TX_NEW_DSD	By Age/Sex: 50+ Female	868
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,655
TX_NEW_DSD	Pregnancy status	1,171
TX_NEW_DSD	Breastfeeding status	600
TX_NEW_DSD	FSW	457
TX_NEW_DSD	MSM	26
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,113
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,120
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,113
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,120
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,113
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,120
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,113



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,120
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	34,483
TX_PVLS_DSD	Denominator: Indication: Routine	34,360
TX_PVLS_DSD	Denominator: Indication: Targeted	122
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	31
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	31
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	31
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	31
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	8,590
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	8,588
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	8,589
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	8,596
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	10,647
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	11,833
TX_RET_DSD	Numerator by Status: Breastfeeding	79
TX_RET_DSD	Denominator by Status: Pregnant	1,323
TX_RET_DSD	Denominator by Status: Breastfeeding	5
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of	628

	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,778
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	777
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,355
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	693
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,145
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	849
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,972
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	6,319



TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	7,433
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	309
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	471
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	4,741
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,918
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	248
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	353
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	4,252
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,463
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	4,456
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,967
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	3,788
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,522
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	42,656
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,973
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,324
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	27,384
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	11,969
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	864
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	478



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	387
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	20,910
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	422
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	20,910
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	422

**Implementing Mechanism Details**

<b>Mechanism ID: 18093</b>	<b>Mechanism Name: Integrated HIV/AIDS Project Kinshasa</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	526,228
----------------------------	---------

**Budget Code Information**



<b>Mechanism ID: 18093</b> <b>Mechanism Name: Integrated HIV/AIDS Project Kinshasa</b> <b>Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	432,438
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	205,927
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	150,876
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	41,666
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	41,668
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	83,335
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>





Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	116,832
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	24,573
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	466,914
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	1,029,637
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	123,557

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	347
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	33,662
PMTCT_ART_DSD	New on ART	231



PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	116
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	33,662
PMTCT_STAT_DSD	Number of new ANC and L&D clients	34,334
PMTCT_STAT_DSD	By Age (Denominator): 10-14	68
PMTCT_STAT_DSD	By Age (Denominator): <15-19	4,426
PMTCT_STAT_DSD	By Age (Denominator): 20-24	8,864
PMTCT_STAT_DSD	By Age (Denominator): 50+	180
PMTCT_STAT_DSD	By Number of known positives: 15-19	10
PMTCT_STAT_DSD	By Number of known positives: 20-24	43
PMTCT_STAT_DSD	By Number of new positives: 15-19	15
PMTCT_STAT_DSD	By Number of new positives: 20-24	47
PMTCT_STAT_DSD	By Number of new negative: 10-14	67
PMTCT_STAT_DSD	By Number of new negative: 15-19	4,341
PMTCT_STAT_DSD	By Number of new negative: 20-24	8,526
PMTCT_STAT_DSD	By Number of new negative: 50+	159
PMTCT_STAT_DSD	By Age (Numerator): 10-14	67
PMTCT_STAT_DSD	By Age (Numerator): 15-19	4,363
PMTCT_STAT_DSD	By Age (Numerator): 20-24	8,616
PMTCT_STAT_DSD	By Age (Numerator): 50+	159
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	5,199
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	5,199
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	5,199
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	5,199
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	15
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	20,213
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	165
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	15



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	15
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	15
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	20,400
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	8
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	8
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	8
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	500
PP_PREV_DSD	Age/sex: 10-14 Male	0
PP_PREV_DSD	Age/sex: 15-19 Male	64
PP_PREV_DSD	Age/sex: 20-24 Male	92
PP_PREV_DSD	Age/sex: 50+ Male	16
PP_PREV_DSD	Age/sex: 10-14 Female	0
PP_PREV_DSD	Age/sex: 15-19 Female	101
PP_PREV_DSD	Age/sex: 20-24 Female	85
PP_PREV_DSD	Age/sex: 50+ Female	3
PP_PREV_DSD	Sum of Age/Sex disaggregates	361
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	18
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	18
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	18
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	18
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	18
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	18
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	17
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	18
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	207,574
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	363



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	374
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	316
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	191
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	364
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	215
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	414
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	590
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	3,060
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	349
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	2



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	240
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	596
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	488
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	37
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	8,630
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	70
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	8,001
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	6,525
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	3,519
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	9,652
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	131



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,301
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	5,588
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	183
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	6,282
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	173
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	38,600
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	229
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	12,447
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	73
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	87
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	100
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	173
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	172
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	232



HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	305
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	211
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	312
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	296
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	451
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	446
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	683
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	593
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	412



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	384
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	240
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	223
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,622
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	66
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	4,381
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	8,562
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	226
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	81





HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	527
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	245
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	95
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	156
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	42
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	59
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	82
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	276



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	277
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	276
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	277
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	276
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	277
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	276
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	277
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	15



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	240
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	240
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	240
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	240
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	215
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	215



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	215
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	215
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	215
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	215
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	215
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	215
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	5,152
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	193
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	5,156
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	199



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	5,152
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	193
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	5,156
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	199
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	5,152
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	193
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	5,156
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	199
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	5,152
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	193
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	5,156
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	199
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	5,064
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	5,064
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	5,064



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	5,064
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	185
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	185
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	185
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	185
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	15



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	197
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	197



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	21
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,685
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,685
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	297
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,861
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	248
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,280





TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	320
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,961
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	259
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,356
GEND_GBV_DSD	Number of people receiving post-GBV care	113
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	113
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	113
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	282
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	16
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	113
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	17
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	139



PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	340
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	270
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	70
PMTCT_EID_DSD	Sum of Infant Age disaggregates	340
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	13,392
TX_CURR_DSD	Age/Sex: 15-19 Male	92
TX_CURR_DSD	Age/Sex: 15-19 Female	201
TX_CURR_DSD	Sum of age/sex disaggregates	293
TX_CURR_DSD	Age/Sex: <1	83
TX_CURR_DSD	Age/Sex: <1-9	656
TX_CURR_DSD	Age/Sex: 10-14 Male	190
TX_CURR_DSD	Age/Sex: 10-14 Female	208
TX_CURR_DSD	Age/Sex: 20-24 Male	118
TX_CURR_DSD	Age/Sex: 50+ Male	1,093
TX_CURR_DSD	Age/Sex: 20-24 Female	579
TX_CURR_DSD	Age/Sex: 50+ Female	1,832
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,047
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,041
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,047
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,041
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,047
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,041
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49,	1,047



	Female, Positive	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,041
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,568
TX_NEW_DSD	By Age/Sex: <1	65
TX_NEW_DSD	By Age/Sex: 1-9	93
TX_NEW_DSD	By Age/Sex: 10-14 Male	64
TX_NEW_DSD	By Age/Sex: 15-19 Male	35
TX_NEW_DSD	By Age/Sex: 20-24 Male	89
TX_NEW_DSD	By Age/Sex: 50+ Male	281
TX_NEW_DSD	By Age/Sex: 10-14 Female	324
TX_NEW_DSD	By Age/Sex: 15-19 Female	111
TX_NEW_DSD	By Age/Sex: 20-24 Female	285
TX_NEW_DSD	By Age/Sex: 50+ Female	372
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,561
TX_NEW_DSD	Pregnancy status	376
TX_NEW_DSD	Breastfeeding status	80
TX_NEW_DSD	FSW	138
TX_NEW_DSD	MSM	96
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	353
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	357
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	353
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	357
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	353
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	357
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49,	353



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	357
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	10,569
TX_PVLS_DSD	Denominator: Indication: Routine	9,602
TX_PVLS_DSD	Denominator: Indication: Targeted	976
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	246
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	244
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	244
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	246
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,400
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,396
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,402
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,395
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,183
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,537
TX_RET_DSD	Numerator by Status: Breastfeeding	68
TX_RET_DSD	Denominator by Status: Pregnant	331
TX_RET_DSD	Denominator by Status: Breastfeeding	76
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of	124



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	942
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	150
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,940
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	146
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,037
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	164
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,204
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,805



TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,124
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	98
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	51
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,523
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	450
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	75
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	42
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,298
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	387
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,274
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	850
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,085
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	718
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	13,392
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	432
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	338
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	9,044
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	3,568
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	430
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	354



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	173
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	6,560
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	135
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	6,560
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	135

### Implementing Mechanism Details

<b>Mechanism ID: 18096</b>	<b>Mechanism Name: Increase Access to Comprehensive HIV/AIDS Prevention, Care, and Treatment Services in DRC under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 10,154,812</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 10,154,812</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	10,154,812

### Cross-Cutting Budget Attribution(s)

Gender: GBV	250,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation



Focus Area:	Post GBV Care
Sub Area:	Implementation
Key Populations: MSM and TG	100,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	150,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Economic Strengthening	445,808
Education	668,611
Human Resources for Health	1,219,387

### Budget Code Information

<b>Mechanism ID:</b>	<b>18096</b>
<b>Mechanism Name:</b>	<b>Increase Access to Comprehensive HIV/AIDS Prevention, Care, and Treatment Services in DRC under PEPFAR</b>
<b>Prime Partner Name:</b>	<b>International Center for AIDS Care and Treatment Programs, Columbia University</b>





Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,630,184
Strategic Area	Budget Code	Planned Amount
Care	HKID	1,663,233
Strategic Area	Budget Code	Planned Amount
Care	HVTB	678,309
Strategic Area	Budget Code	Planned Amount
Care	PDCS	678,309
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	60,624
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	140,418
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	101,043
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	339,155
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	70,320
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	1,336,086
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	2,710,990
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	746,141

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	76,706
PMTCT_ART_DSD	New on ART	719
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	298
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	76,706



	their results)	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	78,296
PMTCT_STAT_DSD	By Age (Denominator): 10-14	137
PMTCT_STAT_DSD	By Age (Denominator): <15-19	12,287
PMTCT_STAT_DSD	By Age (Denominator): 20-24	22,124
PMTCT_STAT_DSD	By Age (Denominator): 50+	36
PMTCT_STAT_DSD	By Number of known positives: 15-19	3
PMTCT_STAT_DSD	By Number of known positives: 20-24	9
PMTCT_STAT_DSD	By Number of new positives: 15-19	35
PMTCT_STAT_DSD	By Number of new positives: 20-24	161
PMTCT_STAT_DSD	By Number of new negative: 10-14	135
PMTCT_STAT_DSD	By Number of new negative: 15-19	12,049
PMTCT_STAT_DSD	By Number of new negative: 20-24	21,518
PMTCT_STAT_DSD	By Number of new negative: 50+	36
PMTCT_STAT_DSD	By Age (Numerator): 10-14	135
PMTCT_STAT_DSD	By Age (Numerator): 15-19	12,085
PMTCT_STAT_DSD	By Age (Numerator): 20-24	21,689
PMTCT_STAT_DSD	By Age (Numerator): 50+	36
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	10,928
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	10,928
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	10,928
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	10,928
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	70
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	39,845
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	474
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	70
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	706



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	18
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	70
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	706
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	18
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	70
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	706
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	18
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	40,387
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	772
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	772
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	772
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	12,660
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	860
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,800
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	473,328



	months	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	2,457
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	2,062
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	3,158
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,909
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	4,093
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,272
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	2,894
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	137
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	2,865
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	103
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	802



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	13,659
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	92
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	12,559
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	10,413
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	19,201
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	106
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	9,270
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	28,725
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	321
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	12,821
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	97
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	13,866
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	502
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	11,588
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	387



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	2,614
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	59,459
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	546
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	138
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	82
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	310
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	329
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	405
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	560
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female,	474



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	748
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	313
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	519
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	459
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,564
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,195
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	58
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,197
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	147
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	565
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female,	416





	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	577
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	84
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	2,170
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	137
HTC_TST_DSD	By Key Population: FSW, Negative	9,425
HTC_TST_DSD	By Key Population: FSW, Positive	401
HTC_TST_DSD	By Key Population: MSM, Negative	998
HTC_TST_DSD	By Key Population: MSM, Positive	28
HTC_TST_DSD	By Key Population: TG, Negative	69
HTC_TST_DSD	By Key Population: TG, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	135
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	12,049
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	21,518
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	161
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	325
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	309
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,103



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	967
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,704
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	68
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	2,373
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	582
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,160
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	102
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	788
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	766
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	158
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	768
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	158



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	766
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	158
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	768
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	158
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	766
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	158
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	768
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	158
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	766
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	158
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	768
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	158
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	2,010
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	2,008
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	159
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	2,010



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	2,008
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	159
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	2,010
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	2,008
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	159
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	2,010
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	144
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	2,008
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	159
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	392
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	14,103
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	429
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	14,098
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	439



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	14,103
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	429
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	14,098
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	439
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	14,103
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	429
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	14,098
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	439
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	14,103
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	429
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	14,098
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	439
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	10,493
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	108
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	10,493
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	108
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	10,493



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	108
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	10,493
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	108
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	404
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	411
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	404
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	411
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	404
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	411
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	404
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	27



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	411
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1,237
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,238
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1,237
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,238
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	1,237
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,238
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	1,237
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,238



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	36
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	7,444
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	7,446
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	287
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,978
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	319
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,834
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	293
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,977
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	326
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,851
GEND_GBV_DSD	Number of people receiving post-GBV care	146
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	150
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	27
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	27





GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	45
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	22
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	25
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	14,158
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,970
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,372
OVC_SERV_DSD	By: Age/sex: Male 18-24	187
OVC_SERV_DSD	By: Age/sex: Male 25+	514
OVC_SERV_DSD	Age/Sex: 10-14 Female	2,007
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,401
OVC_SERV_DSD	By: Age/sex: 18-24 Female	235
OVC_SERV_DSD	By: Age/sex: 25+ Female	1,054
OVC_SERV_DSD	Sum of Age/Sex disaggregates	6,750
OVC_SERV_DSD	Age/Sex: <1	834
OVC_SERV_DSD	Age/Sex: 1-9	4,585
OVC_SERV_DSD	Program Completion: Active	13,167
OVC_SERV_DSD	Program Completion: Graduation	991
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	12,180
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	14,158
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	752
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with	27

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	265
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	29
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	440
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	986
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	807
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	179
PMTCT_EID_DSD	Sum of Infant Age disaggregates	986
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	33,899
TX_CURR_DSD	Age/Sex: 15-19 Male	252
TX_CURR_DSD	Age/Sex: 15-19 Female	632
TX_CURR_DSD	Sum of age/sex disaggregates	884
TX_CURR_DSD	Age/Sex: <1	76
TX_CURR_DSD	Age/Sex: <1-9	2,429
TX_CURR_DSD	Age/Sex: 10-14 Male	322
TX_CURR_DSD	Age/Sex: 10-14 Female	446
TX_CURR_DSD	Age/Sex: 20-24 Male	308
TX_CURR_DSD	Age/Sex: 50+ Male	2,141
TX_CURR_DSD	Age/Sex: 20-24 Female	2,150
TX_CURR_DSD	Age/Sex: 50+ Female	3,053



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,756
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,750
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,756
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,750
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2,756
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,750
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	2,756
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,750
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,200
TX_NEW_DSD	By Age/Sex: <1	66
TX_NEW_DSD	By Age/Sex: 1-9	131
TX_NEW_DSD	By Age/Sex: 10-14 Male	102
TX_NEW_DSD	By Age/Sex: 15-19 Male	53
TX_NEW_DSD	By Age/Sex: 20-24 Male	112
TX_NEW_DSD	By Age/Sex: 50+ Male	670
TX_NEW_DSD	By Age/Sex: 10-14 Female	797
TX_NEW_DSD	By Age/Sex: 15-19 Female	231
TX_NEW_DSD	By Age/Sex: 20-24 Female	810
TX_NEW_DSD	By Age/Sex: 50+ Female	940
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,715
TX_NEW_DSD	Pregnancy status	1,037
TX_NEW_DSD	Breastfeeding status	289
TX_NEW_DSD	FSW	576
TX_NEW_DSD	MSM	37



TX_NEW_DSD	TG	13
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	911
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	905
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	911
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	905
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	911
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	905
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	911
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	905
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	28,155
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	4
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	1
TX_PVLS_DSD	Denominator: Indication: Routine	27,395
TX_PVLS_DSD	Denominator: Indication: Targeted	760
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	188
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	191
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	191
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	197
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	6,840



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	6,836
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	6,856
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	6,873
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,861
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,723
TX_RET_DSD	Numerator by Status: Breastfeeding	179
TX_RET_DSD	Denominator by Status: Pregnant	681
TX_RET_DSD	Denominator by Status: Breastfeeding	201
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	348
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,953
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	440
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,127
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	394
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	2,156



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	482
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,616
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	4,455
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	5,232
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	293
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	205
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	3,568
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,181
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	327
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	246
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	2,981
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	909
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	3,139
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT,	2,098



	Life-long ART, New, Positive	
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	2,675
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,776
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	33,900
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,347
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,125
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	22,302
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	8,673
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,883
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,613
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	268
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	16,609
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	337
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	16,609
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	337

### Implementing Mechanism Details

<b>Mechanism ID: 18097</b>	<b>Mechanism Name: Capacity Strengthening for Strategic Information</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 368,282</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 931,718</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	368,282

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18097</b>		
<b>Mechanism Name: Capacity Strengthening for Strategic Information</b>		
<b>Prime Partner Name: FHI 360</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>





Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	368,282
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18316</b>	<b>Mechanism Name: Strengthening Public Health Capacity and Strategic Information Systems</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information



<b>Mechanism ID:</b>	18316	
<b>Mechanism Name:</b>	Strengthening Public Health Capacity and Strategic Information Systems	
<b>Prime Partner Name:</b>	UNAIDS - Joint United Nations Programme on HIV/AIDS	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18370</b>	<b>Mechanism Name: Global Health Supply Chain Program</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 13,806,519</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 2,100,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 15,906,519</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	13,806,519

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18370</b>		
<b>Mechanism Name: Global Health Supply Chain Program</b>		
<b>Prime Partner Name: Global Health Supply Chain Program</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	1,242,588
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	276,130
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	276,130
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	10,354,889



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,656,782
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

Mechanism ID: 70063	TBD: Yes
REDACTED	

**Implementing Mechanism Details**

Mechanism ID: 70064	TBD: Yes
REDACTED	

**Implementing Mechanism Details**

Mechanism ID: 70065	TBD: Yes
REDACTED	

**Implementing Mechanism Details**

Mechanism ID: 70066	TBD: Yes
REDACTED	

**Implementing Mechanism Details**



<b>Mechanism ID: 70067</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 70068</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 70069</b>	<b>Mechanism Name: RTK</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Remote Medical International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	<b>70069</b>
<b>Mechanism Name:</b>	<b>RTK</b>
<b>Prime Partner Name:</b>	<b>Remote Medical International</b>





Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	1,290,294
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 70070</b>	<b>Mechanism Name: Global Health Supply Chain Technical Assistance</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 70070</b>		
<b>Mechanism Name: Global Health Supply Chain Technical Assistance</b>		
<b>Prime Partner Name: Chemonics International</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	144,228
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	32,050
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	1,187,410
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	32,050
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	1,201,889
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	192,302
Strategic Area	Budget Code	Planned Amount

Approved



Treatment	PDX	0
-----------	-----	---

### Implementing Mechanism Indicator Information

(No data provided.)



**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services			213,667	213,667	0	213,667
ICASS			222,536	222,536	0	222,536
Non-ICASS Administrative Costs			134,670	134,670	0	134,670
Staff Program Travel			171,458	171,458	0	171,458
USG Staff Salaries and Benefits - Internationally Recruited			473,827	473,827	0	473,827
USG Staff Salaries and Benefits - Locally Recruited			523,999	523,999	0	523,999
<b>Total</b>	<b>0</b>	<b>0</b>	<b>1,740,157</b>	<b>1,740,157</b>	<b>0</b>	<b>1,740,157</b>

**U.S. Department of Defense**

Agency Cost	GAP	GHP-State	GHP-USAID	Funding	Applied	Total All
-------------	-----	-----------	-----------	---------	---------	-----------



of Doing Business				Source Total	Pipeline	Funding Sources and Applied Pipeline Amount
Computers/IT Services		5,080		5,080	0	5,080
ICASS		70,688		70,688	0	70,688
Management Meetings/Professional Development		30,550		30,550	0	30,550
Staff Program Travel		27,260		27,260	0	27,260
USG Renovation		24,312		24,312	355,152	379,464
USG Staff Salaries and Benefits - Locally Recruited		139,068		139,068	0	139,068
<b>Total</b>	<b>0</b>	<b>296,958</b>	<b>0</b>	<b>296,958</b>	<b>355,152</b>	<b>652,110</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		547,582		547,582	0	547,582



Computers/IT Services		105,843		105,843	0	105,843
ICASS		757,849		757,849	0	757,849
Management Meetings/Professional Development		169,400		169,400	0	169,400
Non-ICASS Administrative Costs		432,397		432,397	0	432,397
Staff Program Travel		351,650		351,650	0	351,650
USG Staff Salaries and Benefits - Internationally Recruited	825,000	257,055		1,082,055	0	1,082,055
USG Staff Salaries and Benefits - Locally Recruited		998,867		998,867	310,979	1,309,846
<b>Total</b>	<b>825,000</b>	<b>3,620,643</b>	<b>0</b>	<b>4,445,643</b>	<b>310,979</b>	<b>4,756,622</b>

**U.S. Department of State**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		150,000		150,000	0	150,000
Management		45,000		45,000	0	45,000



Approved



Meetings/Professional Development						
Non-ICASS Administrative Costs		97,872		97,872	0	97,872
Staff Program Travel		30,000		30,000	0	30,000
USG Staff Salaries and Benefits - Internationally Recruited		287,719		287,719	185,211	472,930
USG Staff Salaries and Benefits - Locally Recruited		204,000		204,000	0	204,000
<b>Total</b>	<b>0</b>	<b>814,591</b>	<b>0</b>	<b>814,591</b>	<b>185,211</b>	<b>999,802</b>